NanoVibronixNASDAQ: NAOV

NanoVibronix, Inc., through its subsidiary, NanoVibronix Ltd., focuses on the non-invasive biological response-activating devices that target biofilm prevention, wound healing, and pain therapy in the United States, Israel, Europe, Australia, India, and internationally. The company's product portfolio includes UroShield, an ultrasound-based product to prevent bacterial colonization and biofilm in urinary catheters, enhance antibiotic efficacy, and decrease pain and discomfort associated with urinary catheter use. It also offers PainShield, a patch-based therapeutic ultrasound technology to treat pain, muscle spasm, and joint contractures; and WoundShield, a patch-based therapeutic ultrasound device intended to facilitate tissue regeneration and wound healing by using ultrasound to increase local capillary perfusion and tissue oxygenation. It sells its products directly to patients, as well as through distributor agreements. The company was incorporated in 2003 and is headquartered in Tyler, Texas.

NanoVibronix is in the Healthcare sector

NanoVibronix is in the Medical Devices industry

NanoVibronix is headquartered in United States

NanoVibronix initial public offering (IPO) was on 28 May 2015

https://www.nanovibronix.com

No, NanoVibronix is not included in the S&P 500 index

No, NanoVibronix is not included in the NASDAQ 100 index

No, NanoVibronix is not included in the Dow Jones index

No data